The Chesley Initiative: Upcoming Forum Looks at the Road Ahead for Long COVID

Long COVID resists easy definition. It arrives unevenly, lingers unpredictably, and for many patients, exists in the uneasy space between symptom and diagnosis. In the years since the pandemic began, millions (18M in fact) have reported not returning to baseline – fatigue that doesn’t lift, cognitive disruption, respiratory changes that persist without clear explanation. What has been equally persistent is the difficulty of recognition: a condition widely experienced yet inconsistently diagnosed or treated.

Against that backdrop, The Chesley Initiative has emerged as one of the more structured efforts to close that gap – translating research into clinical practice and, just as critically, into awareness. That work comes into sharper focus this Saturday, March 21, when the California Long COVID + IACCI Clinical Implementation Forum will take place at the Mar Monte hotel.

The event is less a standalone conference than a checkpoint in a broader effort to bring coherence, urgency, and legitimacy to a condition that has long operated without all three.

The origins of The Chesley Initiative are not institutional. They are personal, and they are long. Chesley Heymsfield has lived with an infection-associated chronic condition for nearly three decades – an experience that began at 18 and took ten years to formally diagnose. 

That timeline, by her own account (and many others), is not anomalous. It reflects a broader pattern in which patients with post-infectious illnesses move through years of uncertainty, often told their symptoms are rare, isolated, or insufficiently understood.

That premise – that these conditions are not rare, and that patients are not alone – became foundational to the Initiative’s approach. Rather than treating long COVID as an entirely novel phenomenon, the work situates it within a larger category of infection-associated chronic conditions and illnesses (IACCI), connecting it to decades of underrecognized post-viral syndromes. From the outset, the emphasis has been on translation: how to move emerging research out of academic silos and into the hands of clinicians who can act on it.

The early phase of that work took shape in Santa Barbara, where a pilot model was developed to address one of the most persistent gaps in care – diagnosis. The approach is deliberately pragmatic. It centers on equipping primary care providers with the tools to recognize these conditions earlier, rather than relegating them to specialist clinics that cannot meet the scale of demand. From there, the model expands outward: frontline diagnosis paired with access to more advanced centers for complex care.

That framework has since scaled beyond the region. The Initiative has extended into Ventura County and, more recently, into Louisiana through a series of medical education efforts. 

At each stage, the objective remains consistent: shorten the time between symptom onset and diagnosis, and create a system in which data can be captured, aggregated, and used to inform treatment pathways.

A significant inflection point arrived with the development of the IACCI provider manual, created in collaboration with Mount Sinai’s Cohen Center for Recovery and from the efforts of The Chesley Initiative. The manual outlines diagnostic criteria, assessment strategies, and point-of-care interventions – effectively offering clinicians a structured way to approach a condition that has often been treated as diffuse or indeterminate. 

Its recent incorporation into guidance from the U.S. Department of Health and Human Services (HHS) marks a shift from fragmented understanding to something closer to standardization. As Heymsfield notes, the framework is now positioned as a set of recommended clinical guidelines at a national level. 

For patients, that shift carries practical implications: a higher likelihood of recognition, a clearer pathway to care, and a growing acknowledgment that these conditions warrant structured medical response.

The forum this Saturday is designed to operationalize that shift. The program moves from keynote to physician panels to patient discussion, bringing together contributors from Stanford, UCLA, USC, and local health systems. 

Its focus is not theoretical. It is implementation; how to translate a newly established framework into day-to-day clinical practice, and how to ensure that patients are identified earlier in the course of illness.

That work remains incomplete. Key questions persist, particularly around biomarkers and the underlying drivers of disease – whether viral persistence, immune response, or cumulative “multiple hits” contribute to onset and severity. 

Without those answers, treatment pathways remain provisional, and outcomes uneven.

Still, the direction is clearer than it was. What once operated as a diffuse and often dismissed set of symptoms is increasingly being defined within a shared clinical language. The forum reflects that transition – an effort not to conclude the conversation, but to move it forward with greater precision, and with a system beginning, finally, to take shape.  

Admission to the March 21st forum is free and those interested can attend virtually or in-person. Register and find more information at www.chesleyinitiative.org. Visit www.hhs.gov/longcovid/index.html to see the new HHS guide.